JPRN-UMIN000042617招募中未知
Evaluation of lorlatinib efficacy of patients with EML4-ALK - Lorlatinib ctDNA
Japanese Society of Lung Cancer0 个研究点目标入组 150 人开始时间: 2020年12月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients from whom written informed consent regarding study participation was not obtained
研究者
相似试验
进行中（未招募）
1 期
Study of Lorlatinib In Participants with Anaplastic Lymphoma Kinase (ALK) -Positive NSCLCALK-positive metastatic non-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002504-41-GBPfizer Inc.70
招募中
4 期
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCTRI/2023/01/049349Pfizer Inc
进行中（未招募）
1 期
Study of Lorlatinib In Participants with Anaplastic Lymphoma Kinase (ALK)-Positive NSCLCEUCTR2019-002504-41-ITPFIZER INC70
已完成
不适用
Comparative efficacy and safety of lorlatinib and alectinib for ALK rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: systematic review and network meta-analysis.non-small cell lung cacnerJPRN-UMIN000043994Showa University school of medicine2,194
已完成
不适用
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.JPRN-UMIN000011467agasaki Thoracic Oncology Group10